News
INVO Reports Record Third Quarter 2023 Financial Results
Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO)...
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
SARASOTA, Fla. and AVENTURA, Fla., Nov. 10, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. ("NAYA"), a company dedicated to...
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company’s Common Stock Purchase Warrants
SARASOTA, Fla., Nov. 9, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture...
Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event “Accelerating Biotech Value Creation” Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023
An Introduction to NAYA Biosciences with CEO Dr. Daniel TeperManaging unprecedented medical innovation in an era of financial market volatilityIncreasing patient access to breakthrough treatments in oncology, regenerative medicine, and fertilitySARASOTA, Fla. and...
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicineNAYA will seek to scale up profitable revenues in the...
INVO to Participate in the Lytham Partners Fall 2023 Investor Conference
SARASOTA, Fla., Oct. 11, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture...
INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS
SARASOTA, Fla., Sept. 29, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced that its special meeting of shareholders on September 29, 2023 (the "Special Meeting") was convened and then adjourned, without conducting any business, in...
INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET
SARASOTA, Fla., Sept. 28, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture...
INVO Bioscience Announces Pricing of $4.5 Million Public Offering
SARASOTA, Fla., Aug. 4, 2023 -- INVO Bioscience, Inc. (Nasdaq:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture...
INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering
SARASOTA, Fla., March 27, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture...